Cover Image
市場調查報告書

EpiCast Report:大腸躁鬱症(IBS)的流行病學預測

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 317757
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:大腸躁鬱症(IBS)的流行病學預測 EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026
出版日期: 2017年11月01日 內容資訊: 英文 37 Pages
簡介

大腸躁鬱症(IBS),是具有腹部的不舒服和疼痛,膨脹感,排便習慣改變的特徵,慢性復發的腸胃障礙。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)大腸躁鬱症(IBS)和確診的患者數,從2013年的4,077萬人,預計今後10年增加3.9%到4,236萬人。

本報告提供全球主要7個國家的大腸躁鬱症(IBS)調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法 - IBS的總患者數
    • 預測的前提條件與手法 - IBS的亞型區分
  • IBS的流行病學預測
    • IBS的整體患者數
    • IBS的整體患者數(各年齡)
    • IBS的整體患者數(性別)
    • IBS的整體患者數(年齡標準化)
    • IBS的整體患者數(各臨床子類型)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER167-17

Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal (GI) disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional GI disorder. IBS is sub-classified according to the predominant bowel habits. These sub-classifications are constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), mixed-presentation IBS (IBS-M), and unsubtyped IBS (IBS-U).

In the 7MM, the diagnosed prevalent cases of IBS will increase from about 24 million cases in 2016 to around 25 million cases in 2026, at an Annual Growth Rate (AGR) of about 0.3% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and UK), the diagnosed prevalent cases of IBS will increase from around 9 million cases in 2016 to about 9.3 million cases in 2026, at an AGR of around 0.2%.

Italy had the highest age-standardized diagnosed prevalence of IBS in both men (almost 5%) and women (around 10%) in the 7MM. Spain had the lowest age-standardized diagnosed prevalence of IBS in men (nearly 0.9%) and women (around 2%). The difference in the age-standardized diagnosed prevalence of IBS between men and women was the highest in Italy, atover 5% greater in women than in men. Germany had the lowest difference in the age-standardized prevalence of IBS between men and women, at almost 0.8%.

The report "EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global trends for IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS. This report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of IBS segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]) in these markets.

Scope

  • The Irritable bowel syndrome (IBS) EpiCast Report provides an overview of the risk factors and global trends of IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for the total and the diagnosed prevalent cases of IBS. Diagnosed prevalent cases are segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]), and comorbid conditions (anxiety and depression).
  • The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IBS EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IBS therapeutics in each of the markets covered.
  • Understand magnitude of IBS population by disease type and comorbidities.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Irritable Bowel Syndrome: Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Related Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
    • 3.3.1 US 11
    • 3.3.2 5EU 12
    • 3.3.3 Japan 12
  • 3.4 Forecast Methodology 13
    • 3.4.1 Sources 13
    • 3.4.2 Forecast Assumptions and Methods 17
  • 3.5 Epidemiological Forecast for IBS (2016-2026) 23
    • 3.5.1 Total Prevalent Cases of IBS 23
    • 3.5.2 Diagnosed Prevalent Cases of IBS 24
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of IBS 24
    • 3.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS 25
    • 3.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtypes 26
    • 3.5.6 Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity 27
  • 3.6 Discussion 28
    • 3.6.1 Epidemiological Forecast Insight 28
    • 3.6.2 Limitations of the Analysis 29
    • 3.6.3 Strengths of the Analysis 30

4 Appendix 31

  • 4.1 Bibliography 31
  • 4.2 About the Authors 35
    • 4.2.1 Epidemiologist 35
    • 4.2.2 Reviewers 35
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 36
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36
  • 4.3 About GlobalData 37
  • 4.4 Contact Us 37
  • 4.5 Disclaimer 37

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for IBS 8
  • Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies 10
  • Table 3: 7MM, Total Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026 23
  • Table 4: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026 24
  • Table 5: 7MM, Diagnosed Prevalent Cases of IBS by Clinical Subtypes, Both Sexes, Ages ≥18 Years, N, 2016 27
  • Table 6: 7MM, Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity, Both Sexes, Ages ≥18 Years, N, 2016 28

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, 2016 and 2026 5
  • Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of IBS, Ages ≥18 Years, 2016 11
  • Figure 3: 7MM, Sources Used and Not Used, Total Prevalent Cases of IBS 13
  • Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS 14
  • Figure 5: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS Clinical Subtypes 15
  • Figure 6: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS With Comorbidity 16
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016 25
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016 26
Back to Top